Colgate-Palmolive Company (CL) Stock Price & Analysis
Colgate-Palmolive Company (CL) closed at USD 97.39 on Thursday, October 22, 2026, up 4.27% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 93.4; the Oct 22, 2026 session ranged USD 94.56–97.5 on volume of 4,813,564 shares. Market capitalization is $77.64B, with a 52-week range of USD 74.55–99.33 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CL.md
Key facts (CL)
- Last four reported quarters (through Jun 30, 2026): revenue $21.0B, net income $2.04B (9.7% margin), free cash flow $3.86B (SEC filings).
- Valuation: P/E 38.1x (avg 28.2x at the last 3 fiscal year-ends).
- 4 of 80 tracked superinvestors hold CL (13F, Q2 2026): 0 new, 2 added, 1 reduced, 1 unchanged.
- Analysts: Buy (mean 2.10 on a 1–5 scale) (21 analysts), mean target USD 98.15 (range 87–110).
- Total return with dividends: 1Y +27.1% vs S&P 500 +14.9%; 5Y +45.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 0.93, revenue estimate $5.33B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.4B | $18.0B | $19.5B | $20.1B | $20.4B | $21.0B |
| Gross profit | $10.4B | $10.2B | $11.3B | $12.2B | $12.3B | — |
| Operating income | $3.33B | $2.89B | $3.98B | $4.27B | $3.31B | $3.13B |
| Net income | $2.17B | $1.78B | $2.30B | $2.89B | $2.13B | $2.04B |
| EPS (diluted) | $2.55 | $2.13 | $2.77 | $3.51 | $2.63 | — |
| Free cash flow | $2.76B | $1.86B | $3.04B | $3.55B | $3.63B | $3.86B |
| Gross margin | 59.6% | 57.0% | 58.2% | 60.5% | 60.1% | — |
| Operating margin | 19.1% | 16.1% | 20.5% | 21.2% | 16.2% | 14.9% |
| Net margin | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% | 9.7% |
| Revenue growth | +5.8% | +3.1% | +8.3% | +3.3% | +1.4% | — |
| Cash + short-term investments | $832M | $775M | $1.15B | $1.26B | $1.40B | — |
| Total debt | $7.21B | $8.76B | $8.24B | $7.94B | $7.99B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CL)
P/E 38.1x · P/S 3.7x · P/FCF 20.1x · P/B 329.0x · FCF yield 4.97% · Earnings yield 2.62% · Buyback yield (TTM) 1.66%
P/E at fiscal year-ends: Dec 2025 30.1x, Dec 2024 25.9x, Dec 2023 28.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (CL)
4 of 80 tracked investors hold CL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 1.26% | $752M | Added +1.1% |
| Yacktman Asset Management | 0.90% | $72.5M | Added +0.2% | |
| Jensen Investment Management | 0.26% | $10.6M | Reduced -2.9% | |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $1.3M | Unchanged |
Analysts (CL)
Consensus Buy (mean 2.10 on a 1–5 scale), 21 analysts; mean target USD 98.15 (low 87, high 110).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | JP Morgan | Target raised | Overweight | $103 → $104 |
| 2026-10-05 | Wells Fargo | Target lowered | Equal-Weight | $95 → $90 |
| 2026-09-21 | Piper Sandler | Target lowered | Overweight | $98 → $95 |
| 2026-09-08 | RBC Capital | Reiterated | Outperform | $104 |
| 2026-08-03 | UBS | Target raised | Buy | $106 → $109 |
| 2026-08-03 | TD Cowen | Target raised | Hold | $85 → $90 |
| 2026-08-03 | JP Morgan | Target lowered | Overweight | $104 → $103 |
| 2026-08-03 | RBC Capital | Target raised | Outperform | $102 → $104 |
| 2026-08-03 | Evercore ISI Group | Target raised | Outperform | $100 → $101 |
| 2026-07-21 | Barclays | Target raised | Equal-Weight | $80 → $87 |
| 2026-07-16 | JP Morgan | Target raised | Overweight | $96 → $104 |
| 2026-07-16 | UBS | Target raised | Buy | $100 → $106 |
Total return (dividends reinvested) (CL)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +27.1% | +45.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +27.2% | +7.7% |
| Volatility (annualized) | 22.9% | 17.9% |
| Max drawdown | -17.0% (Feb 2026→Apr 2026) | -26.5% (Sep 2024→Oct 2025) |
CL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.93 | $0.92 | +0.3% | $5.33B | 17 |
| Next quarter (ends Dec 2026) | $0.96 | $0.96 | +0.3% | $5.40B | 17 |
| Current fiscal year (ends Dec 2026) | $3.87 | $3.81 | +1.4% | $21.40B | 20 |
| Next fiscal year (ends Dec 2027) | $4.09 | $4.05 | +0.8% | $22.06B | 20 |
CL options: expected move
Options price a move of about ±3.8% (±$3.72) by Oct 30, 2026, which includes earnings on Oct 30, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 32.2% | ±3.8% |
| Nov 6, 2026 | 14 | 25.1% | ±4.1% |
| Nov 13, 2026 | 21 | 25.8% | ±5.1% |
| Nov 20, 2026 | 28 | 24.0% | ±5.4% |
| Nov 27, 2026 | 35 | 23.1% | ±5.8% |
| Dec 4, 2026 | 42 | 22.8% | ±6.3% |
| Dec 18, 2026 | 56 | 22.7% | ±7.2% |
| Jan 15, 2027 | 84 | 21.2% | ±8.2% |
30-day implied volatility 24.2% vs 21.8% realized over the last 30 trading days. Put/call ratio (volume) 1.16. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 97.39 |
|---|---|
| Change | ▲ 4.27% (up) |
| Previous Close | USD 93.4 |
| Open | USD 94.56 |
| Day Range | USD 94.56 – 97.5 |
| 52-Week Range | USD 74.55 – 99.33 |
| Volume | 4,813,564 shares |
| Market Cap | $77.64B |
| Exchange | NYQ |
Technical Analysis (CL)
Nexqual's technical model rates CL "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.33 (overbought) |
| vs SMA50 | Above (USD 89.31) |
| MACD | 1.92 (positive) |
Analyst Ratings (CL)
Wall Street analysts rate CL "Buy" based on 21 analysts, with a mean price target of USD 98.15 (range USD 87–110), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 98.15 |
| High Target | USD 110 |
| Low Target | USD 87 |
| Buy / Hold / Sell | 13 / 8 / 0 |
Earnings (CL)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD 0.93 |
| Revenue Estimate | $5.33B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.99 vs est 0.95 ▲ beat |
| 2026-03-31 | USD 0.97 vs est 0.94 ▲ beat |
| 2025-12-31 | USD 0.95 vs est 0.91 ▲ beat |
| 2025-09-30 | USD 0.91 vs est 0.89 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (CL)
| Total Revenue | $21.05B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.90% |
| Gross Margin | +60.43% |
| Operating Margin | +20.97% |
| Profit Margin | +9.68% |
| ROE | +267.37% |
| Debt / Equity | 13.88 |
| Current Ratio | 1.03 |
| Total Cash | $1.45B |
| Total Debt | $7.86B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $3.86B (18.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (CL)
Nexqual rates Colgate-Palmolive Company's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Mixed — Revenue +1.4% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 21% (last 12 months) |
| Balance Sheet | Critical — $1.40B cash and investments vs $7.99B debt (Dec 2025, SEC) |
| Cash Flow | Strong — FCF $3.86B (last 4 quarters to Jun 2026, SEC), 18% margin |
| Efficiency | Strong — ROE 267%, ROA 15.8% |
Ownership (CL)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +86.38% |
| Shares Outstanding | 797.17M |
| Float | 748.35M |
| Short % of Float | +3.37% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (CL)
Colgate-Palmolive Company is led by Noel R. Wallace, Chairman, CEO & President, per Nexqual as of October 23, 2026 at 09:24 UTC.
| Chairman, CEO & President | Noel R. Wallace |
|---|---|
| Chief Financial Officer | Stanley J. Sutula |
| COO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | Panagiotis Tsourapas |
| Chief Operating Officer of Americas | Shane Grant |
| Chief Technology Officer | Stephan Habif |
Major Backers & Investors (CL)
Notable institutional backers of Colgate-Palmolive Company include Price (T.Rowe) Associates Inc, Morgan Stanley, Fidelity, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 3.5% |
| Morgan Stanley | 2.77% |
| Fidelity | 1.3% |
| NORGES BANK | 1.22% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.56% |
| BlackRock | 8.77% |
| State Street | 5.9% |
| Geode Capital | 2.9% |
| BNY Mellon | 1.7% |
| Deutsche Bank AG | 1.47% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UL | Unilever PLC | USD 67 | ▲ 4.04% |
| EL | Estee Lauder Companies, Inc. (T | USD 107.72 | ▲ 3.92% |
| KVUE | Kenvue Inc. | USD 19.88 | ▲ 4.41% |
| KMB | Kimberly-Clark Corporation | USD 112.32 | ▲ 5.32% |
| CHD | Church & Dwight Company, Inc. | USD 108.86 | ▲ 3.68% |
| PG | Procter & Gamble Company (The) | USD 165.59 | ▲ 5.58% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt